Evidence map›Paper›PMID 33604689›Full record

SynthesisEuropean journal of nuclear medicine and molecular imaging2021

Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review.

R Frood, C Burton, C Tsoumpas, A F Frangi, F Gleeson, C Patel, A Scarsbrook

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. BMC medical imaging · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Integration of [Leukemia · 2025
    Article
  12. Article
  13. Clinical scoring systems, molecular subtypes and baseline [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Review
  14. Article
  15. Article
  16. 2-[Annals of hematology · 2024
    Article
  17. Review
  18. Article
  19. Article
  20. Semiquantitative 2-[Frontiers in medicine · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

R FroodDepartment of Nuclear Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK. russellfrood@nhs.net.ORCID 0000-0003-2681-9922
C BurtonDepartment of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
C TsoumpasLeeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
A F FrangiLeeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
F GleesonDepartment of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
C PatelDepartment of Nuclear Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
A ScarsbrookDepartment of Nuclear Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
University of Leeds · GBLeeds Teaching Hospitals NHS Trust · GBOxford University Hospitals NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo systematically review the literature evaluating clinical utility of imaging metrics derived from baseline fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) for prediction of progression-free (PFS) and overall survival (OS) in patients with classical Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL).

methodsA search of MEDLINE/PubMed, Web of Science, Cochrane, Scopus and clinicaltrials.gov databases was undertaken for articles evaluating PET/CT imaging metrics as outcome predictors in HL and DLBCL. PRISMA guidelines were followed. Risk of bias was assessed using the Quality in Prognosis Studies (QUIPS) tool.

resultsForty-one articles were included (31 DLBCL, 10 HL). Significant predictive ability was reported in 5/20 DLBCL studies assessing SUVmax (PFS: HR 0.13-7.35, OS: HR 0.83-11.23), 17/19 assessing metabolic tumour volume (MTV) (PFS: HR 2.09-11.20, OS: HR 2.40-10.32) and 10/13 assessing total lesion glycolysis (TLG) (PFS: HR 1.078-11.21, OS: HR 2.40-4.82). Significant predictive ability was reported in 1/4 HL studies assessing SUVmax (HR not reported), 6/8 assessing MTV (PFS: HR 1.2-10.71, OS: HR 1.00-13.20) and 2/3 assessing TLG (HR not reported). There are 7/41 studies assessing the use of radiomics (4 DLBCL, 2 HL); 5/41 studies had internal validation and 2/41 included external validation. All studies had overall moderate or high risk of bias.

conclusionMost studies are retrospective, underpowered, heterogenous in their methodology and lack external validation of described models. Further work in protocol harmonisation, automated segmentation techniques and optimum performance cut-off is required to develop robust methodologies amenable for clinical utility.

Indexed as

Lymphoma, Large B-Cell, DiffusePositron Emission Tomography Computed TomographyFluorodeoxyglucose F18HumansPositron-Emission TomographyPrognosisRetrospective StudiesTreatment OutcomeTumor BurdenFluorodeoxyglucose F18Diffuse large B-cell lymphomaHodgkin lymphomaOutcome predictionPET-CTRadiomics

Identifiers

PMID33604689
PMCPMC8426243
OpenAlexW3131237683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.